+------------------------------------------------------------------------------+
Teva to Buy NuPathe for $3.65/Shr; Endo/NuPathe Pact Terminated 2014-01-21 12:03:09.756 GMT
By Joanna Ossinger Jan. 21 (Bloomberg) -- Teva to buy NuPathe for $3.65/shr cash vs PATH closing price $4.38 on Fri.; Endo receives $5m termination fee. * NOTE: Jan. 8, Teva Seeks to Outbid Endo With $150 Million NuPathe Offer {NSN MZ3PES6S972E <go>} * PATH halted for news Statements: {NSN MZR2O0MEQTYA <go>}, {NSN MZR2PQ3MMTC0 <go>}
Link to Company News:{PATH US <Equity> CN <GO>} Link to Company News:{TEVA IT <Equity> CN <GO>} Link to Company News:{ENDP US <Equity> CN <GO>}
For Related News and Information: First Word scrolling panel: {FIRST<GO>} First Word newswire: {NH BFW<GO>}
To contact the editor responsible for this story: Joanna Ossinger at +1-212-617-7789 or jossinger@bloomberg.net